Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy
Authors:
- F. Canouï-PoitrineFCF. Canouï-Poitrine
- S. ReffetSRS. Reffet
- G. Mills-JoncourGMG. Mills-Joncour
- E. MorelonEME. Morelon
- C. ColinCCC. Colin
- C. ThivoletCTC. Thivolet
- 1 April 2010
- journal article
- research article
- Published by Elsevier in Diabetes & Metabolism
- Vol. 36 (2) , 152-157
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Modern-Day Clinical Course of Type 1 Diabetes Mellitus After 30 Years' DurationArchives of internal medicine (1960), 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Skin AutofluorescenceDiabetes Care, 2008
- Clinical Factors Associated With Resistance to Microvascular Complications in Diabetic Patients of Extreme Disease DurationDiabetes Care, 2007
- Skin Autofluorescence as a Noninvasive Marker of Vascular Damage in Patients With Type 2 DiabetesDiabetes Care, 2006
- Intensive Diabetes Therapy and Carotid Intima–Media Thickness in Type 1 Diabetes MellitusNew England Journal of Medicine, 2003
- Renal catabolism of advanced glycation end products: The fate of pentosidineKidney International, 1998
- Advanced glycosylation end products in diabetic renal and vascular diseaseAmerican Journal of Kidney Diseases, 1995
- Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus.Journal of Clinical Investigation, 1993
- Accumulation of Maillard reaction products in skin collagen in diabetes and aging.Journal of Clinical Investigation, 1993